Biosimilar Antibodies

ALT-836 is a recombinant chimeric monoclonal antibody of the IgG4κ subclass that specifically targets human tissue factor (TF) and the TF-FVIIa complex. By binding to these entities, ALT-836 effectively prevents the association and subsequent activation of Factor X (FX), thereby inhibiting the generation of thrombin. This mechanism plays a crucial role in modulating thrombotic processes, making ALT-836 an essential tool for research in coagulation and cardiovascular disorders.

CTX-471 is a fully human monoclonal antibody targeting CD137, a receptor involved in the regulation of immune responses. This antibody demonstrates high binding affinity to recombinant CD137 from various species, with dissociation constants (Kd) of 50 nM for human, 61 nM for cynomolgus macaque, and 748 nM for mouse CD137. CTX-471 is primarily utilized in research focused on immunomodulation and oncology, offering a valuable tool for studies aimed at understanding and manipulating immune pathways in cancer therapy.

Mipasetamab is an IgG1κ monoclonal antibody specifically designed to target AXL, a member of the TAM family of receptor tyrosine kinases. This antibody plays a crucial role in the synthesis of ADCT-601 (Mipasetamab uzoptirine), an antibody-drug conjugate (ADC) that selectively binds to the AXL receptor. ADCT-601 demonstrates significant antitumor activity, leveraging the specificity of Mipasetamab to deliver cytotoxic agents directly to AXL-expressing tumor cells, thereby enhancing therapeutic efficacy while minimizing off-target effects. This product is pivotal for research focused on the development of targeted cancer therapies, particularly in studies investigating the role of AXL in cancer progression and resistance mechanisms.

The Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is a humanized monoclonal antibody targeting LAMP1/CD107a. This antibody serves as the antibody component of the therapeutic SAR-428926. It is characterized as Human IgG1 kappa and can also be utilized as an isotype control in various experimental setups. This product is designed for research applications, focusing on the study of lysosomal associated membrane protein 1 (LAMP1), which is critical in cellular processes such as autophagy and lysosome stabilization.

Gantenerumab is a fully humanized IgG1 monoclonal antibody designed to target amyloid-beta (Aβ) fibrils and plaques, which are hallmark features in the pathology of Alzheimer's disease. This antibody exhibits high specificity for Aβ aggregates, making it an essential tool for research focused on the mechanisms and therapeutic interventions of Alzheimer's disease. Gantenerumab is particularly valuable in studies aiming to understand the role of amyloid plaques in neurodegeneration and as a potential therapeutic agent in clinical settings.

Torapsel (42-89-glycoprotein; WAY164339) is a fusion protein that incorporates elements of immunoglobulin. This biologic is specifically designed for use in experimental studies focused on the prevention of ischemia-reperfusion injury. Torapsel's unique structure and functional properties make it a valuable tool for researchers investigating cellular mechanisms and therapeutic interventions related to tissue damage following restored blood flow after ischemic events.

Crefmirlimab is a humanized minibody specifically targeting CD8. This minibody retains the target specificity characteristic of full-length antibodies while lacking immune effector functions, rendering it biologically inert. This feature makes it particularly suitable for detailed studies of CD8 interactions without eliciting an immune response, ideal for controlled experimental setups in immunology and oncology research.

Lexatumumab (HGS-ETR 2) is a human monoclonal antibody of the IgG4κ subtype that functions as an agonist to TRAIL receptor 2 (TRAIL-R2, also known as DR5 or APO-2). This antibody is specifically designed to induce apoptosis in cells exhibiting malignant mesothelioma characteristics. It is primarily utilized in research focused on understanding and treating malignant pleural mesothelioma (MPM), offering significant value in studies aimed at exploring targeted cancer therapies.

Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody engineered to specifically neutralize the alpha-toxin (alpha-hemolysin; Hla) produced by Staphylococcus aureus. By targeting an N-terminal epitope of alpha-toxin, Tosatoxumab inhibits the oligomerization process essential for the formation of functional toxin pores. This antibody offers promising applications in passive immunotherapy for Staphylococcus aureus pneumonia, serving as an adjunctive treatment alongside standard antibiotic therapies.

Atibuclimab is a chimeric monoclonal antibody targeting CD14, comprised of murine variable regions and human IgG4 Fc regions. This antibody is specifically designed for research purposes in amyotrophic lateral sclerosis (ALS). Atibuclimab effectively moderates lipopolysaccharide (LPS)-induced symptoms and robustly suppresses the release of proinflammatory cytokines induced by LPS. Concurrently, it moderately delays the secretion of anti-inflammatory cytokines, including soluble TNF receptor type I and IL-1 receptor antagonist, providing a distinct profile of cytokine regulation. This dual action makes Atibuclimab a valuable tool for investigating inflammatory pathways and their modulation in ALS research.

Rolistobart is a humanized monoclonal antibody of the immunoglobulin G4-kappa subtype, specifically targeting LILRB4/CD85k. It functions as both an immunostimulant and an antineoplastic agent, designed to modulate immune responses and inhibit tumor growth. This antibody is utilized primarily in the study of cancer immunotherapy, focusing on its potential to enhance immune system recognition and destruction of cancer cells.

Olintatug is a chimeric humanized antibody of the IgG1κ subtype that specifically targets KAAG1. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Maftivimab (REGN3470-3471-3479), also known as Atoltivimab and Odesivimab under the brand name Inmazeb, is an FDA-approved monoclonal antibody cocktail designed to inhibit Filovirus activity. This biologic is specifically targeted against the Zaire ebolavirus, making it highly relevant for research focused on this pathogen. Maftivimab is utilized in studies investigating the mechanisms of viral entry and replication, as well as in the development of therapeutic strategies for Ebola virus infection.

The Anti-IL-20 Antibody is a humanized monoclonal antibody produced in Chinese hamster ovary (CHO) cells, specifically designed to target IL-20. This antibody consists of a human IgG1 type heavy chain and a human kappa type light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Emerfetamab is a monoclonal antibody designed to target both CD3E and CD33 molecules. This dual specificity enables it to engage T cells via CD3E and simultaneously recognize myeloid cells through CD33, making it a valuable tool in the research of immune cell interactions and potential therapeutic applications in hematological malignancies.

Nezastomig is a human IgG4 κ monoclonal antibody targeting FOLH1/CD28. For accurate experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for specificity to FOLH1/CD28, making it suitable for a range of research applications investigating the role of this target in various biological processes.

Inebilizumab is a monoclonal antibody targeting CD19 with enhanced capabilities for antibody-dependent cell-mediated cytotoxicity (ADCC) directed against B cells. This antibody is utilized in research focused on multiple sclerosis and neuromyelitis optica, providing a valuable tool for studying disease mechanisms and potential therapeutic interventions in these conditions.

Navicixizumab (OMP-305B83) is a bispecific antibody designed to inhibit both vascular endothelial growth factor (VEGF) and Delta-like ligand 4 (DLL4). This dual inhibition mechanism makes it a potent candidate for use in oncology research, particularly in studies involving ovarian, primary peritoneal, or fallopian tube cancers. Navicixizumab has shown potential for use in combination with Paclitaxel, enhancing its applicability in therapeutic research protocols aimed at targeting cancer angiogenesis and tumor growth.

The Anti-CD2 Antibody (CB.219) is a chimeric mouse monoclonal antibody of the IgG2b, κ subclass, specifically designed to target human CD2. This antibody is ideal for research applications requiring precise CD2 modulation or detection. For accurate experimental control, it is recommended to use the Mouse IgG2b kappa, Isotype Control.

Nivolumab is a human IgG4 monoclonal antibody that inhibits the programmed death receptor-1 (PD-1) pathway, offering therapeutic benefits in the management of advanced (metastatic) non-small cell lung cancer. This antibody functions by blocking the interaction between PD-1 and its ligands, thereby enhancing the immune response against tumor cells. It is specifically designed for the treatment of patients with advanced stages of this malignancy, where it has shown efficacy in improving patient outcomes.

Dazukibart is a humanized IgG1κ monoclonal antibody derived from mouse sources, specifically designed to target Interferon beta 1 (IFNB1). This antibody is engineered to bind selectively to IFNB1, making it an essential tool for research focused on the role of this cytokine in immune response and inflammatory processes. Dazukibart is suitable for a variety of experimental applications, including functional assays and immunological studies aimed at elucidating the biological pathways mediated by IFNB1.

The Anti-Mesothelin Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets mesothelin, a protein frequently overexpressed in various forms of cancer, including mesothelioma and ovarian carcinoma. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and it has a predicted molecular weight of 150 kDa. For isotype control purposes, reference is made to the Human IgG1 kappa, Isotype Control. This antibody serves as a valuable tool for research focused on cancer biology and the therapeutic targeting of mesothelin-positive tumors.

Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody designed to specifically target and inhibit CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). By antagonizing the inhibitory checkpoints mediated by CTLA-4 signaling, Zalifrelimab enhances immune cell activation, potentially amplifying antitumor immune responses. This antibody is utilized in research focused on immunotherapy and the modulation of immune checkpoints in oncology.

Intetumumab (CNTO 95) is a glycoengineered anti-EGFR monoclonal antibody designed to enhance antibody-dependent cellular cytotoxicity (ADCC). This potent therapeutic tool is specifically utilized in cancer research to investigate the mechanisms of tumor cell inhibition mediated by EGFR targeting.

Varisacumab (R 84) is a monoclonal antibody designed for biochemical research applications. This antibody offers specificity in targeting and studying molecular interactions, making it a valuable tool for a wide range of biochemical investigations.

Visilizumab is a humanized monoclonal IgG2 antibody with low Fc receptor binding affinity, targeting CD3E. This recombinant antibody is designed for the study of immune-mediated gastrointestinal disorders, including ulcerative colitis and Crohn's disease. Its specificity for CD3E makes it a valuable tool in research focused on T-cell mediated responses in these conditions.

Edrecolomab (Panorex) is a murine monoclonal antibody that targets the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and various carcinomas. This antibody exhibits anti-tumor activity, making it particularly useful in the study of colorectal carcinoma.

Ranevetmab (NV-01) is a caninized monoclonal antibody targeting nerve growth factor (NGF). This antibody is specifically engineered for use in canine models to investigate and alleviate pain associated with degenerative joint disease (DJD). Ranevetmab binds selectively to NGF, a key mediator in the pathway of pain, thereby inhibiting its activity and providing a valuable tool for research into novel pain therapies in veterinary medicine.

Flanvotumab (IMC-20D7S) is a human monoclonal antibody designed to specifically target tyrosinase-related protein 1 (TYRP1), which is predominantly expressed in melanocytes and melanoma cells. This antibody mediates its effects through the mechanism of antibody-dependent cell-mediated cytotoxicity (ADCC), engaging the body's natural killer cells to destroy tumor cells. Flanvotumab demonstrates significant anti-tumor activity and is well-tolerated, making it a valuable tool for research in melanoma therapeutics.

Emicizumab is a bispecific monoclonal antibody designed to mimic the function of activated factor VIII by bridging activated factor IX and factor X, effectively restoring hemostasis. This antibody is utilized primarily in research focused on hemophilia A, offering a novel approach to studying and potentially managing this bleeding disorder.

Ozanezumab (GSK1223249) is a monoclonal antibody targeting Nogo-A, a protein known to inhibit neurite outgrowth. This antibody is primarily utilized in the study of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), providing a valuable tool for exploring the mechanisms underlying these diseases and potential therapeutic approaches.

Ontuxizumab (MORAb-004) is a humanized IgG1 kappa monoclonal antibody targeting endosialin (also known as TEM-1 or CD248). This antibody exhibits antitumor properties by specifically binding to endosialin, a protein predominantly expressed in tumor vasculature and certain tumor stromal cells. Ontuxizumab is utilized primarily in cancer research to investigate its therapeutic potential and mechanism of action in tumor inhibition.

The Anti-EphB2 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the EphB2 receptor, a member of the Eph family of receptor tyrosine kinases involved in developmental processes and disease states such as cancer. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is suitable for use in various immunological assays to study EphB2 function and expression.

Odesivimab is a human monoclonal antibody specifically designed to target the glycoprotein of the Ebola virus. It exhibits a high affinity for the recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain, with a dissociation constant (K_D) of 7.74 nM. This antibody is ideal for use in research focused on Ebola virus infection, aiding in the study of viral entry mechanisms and immune response.

Neihulizumab (ALTB-168) functions as an agonistic antibody targeting the immune checkpoint receptor CD162, also known as PSGL-1. By binding to this receptor, Neihulizumab effectively mediates the downregulation of activated T-cells. This antibody is primarily utilized in research focusing on steroid-refractory acute graft-versus-host disease (SR-aGVHD), as well as studies related to psoriasis, psoriatic arthritis, and ulcerative colitis. Its unique mechanism and specificity make it a valuable tool in the investigation of immune response modulation in these conditions.

Adakitug (BMS-986253) is a recombinant human monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target CXCL8/IL-8. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 144.94 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cabiralizumab (FPA 008) is a monoclonal antibody targeting CSF1R (Colony Stimulating Factor 1 Receptor), designed to modulate the immune system by enhancing T cell infiltration and promoting antitumor immune responses. This antibody effectively inhibits the activation of osteoclasts, thereby preventing bone destruction, making it a valuable tool in the study of rheumatoid arthritis. Additionally, Cabiralizumab has been utilized in combination with Nivolumab in the exploration of therapeutic strategies for lung cancer, highlighting its potential in oncology research settings.

Talacotuzumab (JNJ 56022473; CSL 362) is a fully humanized IgG1 monoclonal antibody engineered to neutralize CD123. It exhibits dissociation constants (K_Ds) of 0.43 nM for CD123, 188 nM for CD32b/c, 46 nM for CD16-158F, and 16.8 nM for CD16-158V, indicating high specificity and affinity for these targets. The antibody effectively inhibits interleukin-3 (IL-3) binding to CD123, thereby blocking IL-3 mediated signaling pathways in targeted cells. The Fc region of Talacotuzumab has been specifically mutated to enhance its affinity for CD16 (FcγRIIIa), which significantly amplifies its capability to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This modification enhances its therapeutic potential, particularly in oncology applications. In vivo studies demonstrate that Talacotuzumab significantly reduces leukemic cell proliferation in acute myeloid leukemia (AML) xenograft mouse models, highlighting its potential as a therapeutic agent in hematological malignancies.

The Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the MSPR/RON/CD136 antigen. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 156.7 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control should be utilized as the isotype control for this antibody. This product is essential for researchers focusing on the biological pathways and disease associations involving the MSPR/RON/CD136 protein.

Ixotatug is a monoclonal antibody designed to selectively target human Claudin-6 (CLDN6), a tight junction protein frequently overexpressed in various tumor types. By binding to CLDN6, Ixotatug disrupts critical signaling pathways within tumor cells, thereby exerting potent antitumor effects. This antibody is particularly valuable for research focused on the pathophysiology and therapeutic targeting of CLDN6-associated cancers.

The Anti-pan-Glypican Antibody (HS20) is a human monoclonal antibody of the IgG1, κ subclass, specifically designed to target human pan-Glypican. For accurate isotype control in experimental setups, it is recommended to use Mouse IgG1 kappa Isotype Control. This antibody is suitable for a range of research applications, providing specificity and reliability in targeting the pan-Glypican, which is implicated in various cellular processes and disease states.

Riltovetbart is a canine-derived monoclonal antibody of the IgG2 κ class, specifically targeting interleukin-13 (IL13) in the Canlupfam species. This antibody is engineered for high specificity and affinity, making it an ideal tool for detailed studies of IL13's role in immune responses and potential therapeutic interventions in related canine disorders.

The Anti-MMP9 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target MMP9 (Matrix Metallopeptidase 9). This antibody is constructed from a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 144.76 kDa. For isotype control, researchers should use the Human IgG2 kappa, Isotype Control, which serves as an appropriate reference for assessing the specificity and binding characteristics of the Anti-MMP9 Antibody in various experimental setups. This product is suitable for a range of applications in the study of enzyme regulation and tissue remodeling processes.

Naptumomab is a fusion protein incorporating a tumor-targeting superantigen (TTS), designed to enhance the immune system's ability to detect and eliminate tumor cells. This biologic is particularly utilized in research focused on refractory solid tumors, including renal cell carcinoma, providing a valuable tool for investigations into novel cancer immunotherapies.

Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody engineered to specifically target and bind to tumor necrosis factor-alpha (TNF-α). By binding to TNF-α, Infliximab inhibits its interaction with its receptors, TNFR1 and TNFR2, effectively modulating the inflammatory response. This antibody is widely utilized in the study of autoimmune and chronic inflammatory diseases, as well as in research focused on diabetic neuropathy. Infliximab serves as a critical tool in elucidating the pathophysiological mechanisms underlying these conditions and in the development of therapeutic strategies.

FR104 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CD28. This antibody consists of a human IgG2 heavy chain and a human kappa light chain, with an estimated molecular weight of 145 kDa. For experimental control purposes, Human IgG2 kappa, Isotype Control is recommended.

Catumaxomab is a trifunctional IgG2 antibody engineered from mouse and rat heavy and light chains. This antibody exhibits specific binding to human epithelial cell adhesion molecule (EpCAM) and the T-cell receptor CD3. Additionally, the Fc region of Catumaxomab demonstrates affinity for Fc gamma receptors FcγR1 (CD64), FcγRIIA (CD32a), and FcγRIII (CD16). Due to its unique binding properties, Catumaxomab is particularly valuable in the study of epithelial cancers, serving as a potent tool in anti-tumor research applications.

Xentuzumab (BI836845) is a recombinant human monoclonal antibody specifically designed to target and neutralize the insulin-like growth factors IGF1 and IGF2. By binding to these ligands, Xentuzumab effectively inhibits their role in promoting cellular growth and proliferation. Additionally, this antibody suppresses the activation of AKT, a critical kinase in the PI3K/AKT signaling pathway, further impeding oncogenic signaling. This dual mechanism of action makes Xentuzumab a valuable tool in research focused on cancer biology, particularly in studies exploring the regulation of growth factor-mediated signal transduction and its impact on cellular behaviors.